Trials / Completed
CompletedNCT04575467
A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)
A 2-Stage Adaptive Design, Phase 2 Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal and Thigh Subcutaneous Fat (Stage 1)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Caliway Biopharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Accepted
Summary
The Stage 1 of this phase 2 study is an open-label single ascending dose (SAD) study. The primary objectives are to evaluate the safety and tolerability of injection lipolysis with CBL-514. It will be followed by a parallel-arm multiple-dose design in Stage 2.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CBL-514 | CBL-514 will be administered via injection into the subcutaneous adipose layer. |
Timeline
- Start date
- 2020-12-09
- Primary completion
- 2021-11-15
- Completion
- 2021-12-08
- First posted
- 2020-10-05
- Last updated
- 2024-08-09
- Results posted
- 2024-03-28
Locations
1 site across 1 country: Australia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04575467. Inclusion in this directory is not an endorsement.